Continued treatment with nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from SENSCIS-ON

Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial

(2021) Kristin B Highland et al.   Lancet Respiratory Medicine

SYSTEMIC SCLEROSIS‐ASSOCIATED INTERSTITIAL LUNG DISEASE: How to incorporate two Food and Drug Administration‐approved therapies in clinical practice

(2021) Dinesh Khanna et al.   Arthritis & Rheumatology

A Drug–Drug Interaction Study to Investigate the Effect of Nintedanib on the Pharmacokinetics of Microgynon (Ethinylestradiol and Levonorgestrel) in Female Patients with Systemic Sclerosis-Associated Interstitial Lung Disease

(2021) Madelon C. Vonk et al.   EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS

The natural history of progressive fibrosing interstitial lung diseases

(2020) K.K. Brown et al.   EUROPEAN RESPIRATORY JOURNAL

Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database

(2020) Anna-Maria Hoffmann-Vold et al.   ANNALS OF THE RHEUMATIC DISEASES

Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease

(2019) Oliver Distler et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tracking Impact of Interstitial Lung Disease in Systemic Sclerosis in a Complete Nationwide Cohort

(2019) Anna-Maria Hoffmann-Vold et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON

(2018) Bruno Crestani et al.   Lancet Respiratory Medicine

Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts

(2018) Elizabeth R Volkmann et al.   ANNALS OF THE RHEUMATIC DISEASES

Short-Term Pulmonary Function Trends Are Predictive of Mortality in Interstitial Lung Disease Associated With Systemic Sclerosis

(2017) Nicole S. Goh et al.   Arthritis & Rheumatology

Incidences and Risk Factors of Organ Manifestations in the Early Course of Systemic Sclerosis: A Longitudinal EUSTAR Study

(2016) Veronika K. Jaeger et al.   PLoS One

Predictors of mortality in rheumatoid arthritis-associated interstitial lung disease

(2015) Joshua J. Solomon et al.   EUROPEAN RESPIRATORY JOURNAL

Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis

(2014) Luca Richeldi et al.   NEW ENGLAND JOURNAL OF MEDICINE

2013 Classification Criteria for Systemic Sclerosis: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative

(2013) Frank van den Hoogen et al.   ARTHRITIS AND RHEUMATISM

Reliability and validity of the university of california, los angeles scleroderma clinical trial consortium gastrointestinal tract instrument

(2009) Dinesh Khanna et al.   ARTHRITIS AND RHEUMATISM